| Literature DB >> 30309848 |
Tala Shahin1,2, Dominik Aschenbrenner3, Deniz Cagdas4,5, Sevgi Köstel Bal1,2,6, Cecilia Domínguez Conde1,2, Wojciech Garncarz1,2, David Medgyesi1,2, Tobias Schwerd3,7, Betül Karaatmaca4, Pınar Gur Cetinkaya4, Saliha Esenboga4, Stephen R F Twigg8, Andrew Cant9, Andrew O M Wilkie8, Ilhan Tezcan4,5, Holm H Uhlig10,11, Kaan Boztug12,2,13,14.
Abstract
Hyper-IgE syndromes comprise a group of inborn errors of immunity. STAT3-deficient hyper-IgE syndrome is characterized by elevated serum IgE levels, recurrent infections and eczema, and characteristic skeletal anomalies. A loss-of-function biallelic mutation in IL6ST encoding the GP130 receptor subunit (p.N404Y) has very recently been identified in a singleton patient (herein referred to as PN404Y) as a novel etiology of hyper-IgE syndrome. Here, we studied a patient with hyper-IgE syndrome caused by a novel homozygous mutation in IL6ST (p.P498L; patient herein referred to as PP498L) leading to abrogated GP130 signaling after stimulation with IL-6 and IL-27 in peripheral blood mononuclear cells as well as IL-6 and IL-11 in fibroblasts. Extending the initial identification of selective GP130 deficiency, we aimed to dissect the effects of aberrant cytokine signaling on T-helper cell differentiation in both patients. Our results reveal the importance of IL-6 signaling for the development of CCR6-expressing memory CD4+ T cells (including T-helper 17-enriched subsets) and non-conventional CD8+T cells which were reduced in both patients. Downstream functional analysis of the GP130 mutants (p.N404Y and p.P498L) have shown differences in response to IL-27, with the p.P498L mutation having a more severe effect that is reflected by reduced T-helper 1 cells in this patient (PP498L) only. Collectively, our data suggest that characteristic features of GP130-deficient hyper-IgE syndrome phenotype are IL-6 and IL-11 dominated, and indicate selective roles of aberrant IL-6 and IL-27 signaling on the differentiation of T-cell subsets. CopyrightEntities:
Mesh:
Substances:
Year: 2018 PMID: 30309848 PMCID: PMC6395342 DOI: 10.3324/haematol.2018.194233
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941